| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.0958-7578.2004.00478.X |
| P698 | PubMed publication ID | 15043592 |
| P2093 | author name string | S J Machin | |
| I J Mackie | |||
| A S Lawrie | |||
| H Yarranton | |||
| G Purdy | |||
| P2860 | cites work | Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura | Q24614077 |
| Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura | Q33328894 | ||
| Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? | Q33333811 | ||
| Von Willebrand factor--cleaving protease activity in congenital thrombotic thrombocytopenic purpura | Q33335798 | ||
| Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. | Q33338940 | ||
| Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura | Q33343048 | ||
| Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias | Q33346559 | ||
| Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura | Q33348253 | ||
| Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group | Q33496619 | ||
| Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura | Q33496995 | ||
| von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome | Q33504463 | ||
| Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy | Q34962428 | ||
| Resistance development to fluoroquinolones in Europe | Q41214327 | ||
| Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma. | Q50500906 | ||
| Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. | Q53656605 | ||
| Coagulation factor levels in solvent/detergent-treated plasma | Q73110224 | ||
| In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma | Q77467530 | ||
| Universal solvent/detergent-treated fresh frozen plasma (Uniplas--rationale and clinical properties | Q78370910 | ||
| P433 | issue | 1 | |
| P921 | main subject | thrombocytopenia | Q585285 |
| thrombotic thrombocytopenic purpura | Q1426491 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 39-44 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Transfusion Medicine | Q15758505 |
| P1476 | title | Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura | |
| P478 | volume | 14 |
| Q83232961 | 4 Plasma for Therapeutic Use |
| Q37776318 | A comparison of methods of pathogen inactivation of FFP |
| Q33406892 | ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment |
| Q91327728 | Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura |
| Q37606107 | Clinical trials for pathogen reduction in transfusion medicine: a review |
| Q43744630 | Coagulation factor content of plasma produced from whole blood stored for 24 hours at ambient temperature: results from an international multicenter BEST Collaborative study. |
| Q33368173 | Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light |
| Q87181620 | Coagulation factors and inhibitors in thawed plasma stored at 1-6 °C for 5 days in China |
| Q64242101 | Combination of Fresh Frozen Plasma and Cryosupernatant Plasma for Therapeutic Plasma Exchange in Thrombotic Thrombocytopenic Purpura: A Single Institution Experience |
| Q90520174 | Comparison of ADAMTS13 and Von Willebrand factor levels and activities, and plasminogen levels, in plasma products currently available for the treatment of thrombotic thrombocytopenic purpura in South Africa |
| Q33376161 | Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura |
| Q33426823 | Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry. |
| Q33365640 | Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. |
| Q34038164 | Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience |
| Q92088764 | Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single center |
| Q38736033 | Evaluating the impact of the ABO blood group on the clinical outcome of thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency |
| Q26748355 | Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document |
| Q96813845 | Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data |
| Q33374478 | Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development |
| Q33426377 | Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura. |
| Q104063169 | Plasma exchange and thrombotic microangiopathies: From pathophysiology to clinical practice |
| Q50469599 | Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. |
| Q46423794 | Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments |
| Q37209117 | Recommendations for the transfusion of plasma and platelets |
| Q37062415 | Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma |
| Q33415693 | Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation |
| Q38213153 | Solvent/detergent plasma: pharmaceutical characteristics and clinical experience |
| Q24614152 | The influence of riboflavin photochemistry on plasma coagulation factors |
| Q33369832 | The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma |
| Q39230229 | Therapeutic plasmas available worldwide |
| Q41869417 | Thrombin Generation Capacity of Methylene Blue-Treated Plasma Prepared by the Theraflex MB Plasma System |
| Q33376071 | Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency |
| Q33418125 | Trends in the diagnosis and management of TTP: European perspective |
| Q37166900 | Updates on pathogen inactivation of plasma using Theraflex methylene blue system |
| Q36874269 | Virus-inactivated plasma - Plasmasafe: a one-year experience |
| Q50452728 | [Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP]. |
| Q81419662 | [Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems] |
Search more.